1286 studies found for:    Multiple Sclerosis
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Natalizumab Treatment of Progressive Multiple Sclerosis
Conditions: Primary Progressive Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Intervention: Drug: Natalizumab
2 Completed
Has Results
REbif FLEXible Dosing in Early Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Interventions: Drug: RNF;   Drug: Placebo
3 Completed
Has Results
Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome
Condition: Multiple Sclerosis
Interventions: Drug: Glatiramer Acetate (DB);   Drug: Placebo;   Drug: Glatiramer Acetate (OL)
4 Recruiting Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Device: Trap Myelin Test
5 Unknown  Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Other: Physical exercise training
6 Recruiting A Phase 2b/3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis
Conditions: Multiple Sclerosis, Secondary Progressive;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Relapse Free
Interventions: Drug: masitinib;   Drug: placebo
7 Recruiting Effects of the Cross-Training in Patients With Multiple Sclerosis
Conditions: Multiple Sclerosis;   Weakness;   Fatigue
Interventions: Other: Cross-Training healthy subjects;   Other: Cross-Training multiple sclerosis;   Other: Standard-training multiple sclerosis
8 Completed
Has Results
Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Atorvastatin;   Drug: Placebo
9 Completed
Has Results
Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Fingolimod;   Drug: Placebo
10 Completed
Has Results
Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Interferon beta 1-a;   Drug: glatiramer acetate;   Other: placebo
11 Completed Supported Treadmill Training for Progressive Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Other: Body-weight supported treadmill training
12 Completed Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
Conditions: Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Interventions: Drug: natalizumab;   Other: standard of care
13 Completed
Has Results
BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1b (Betaseron, BAY86-5046)
14 Active, not recruiting Gene Expression Profiles in Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Intervention: Procedure: Blood Draw
15 Completed Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple Sclerosis
Conditions: Multiple Sclerosis;   Vitamin D Deficiency
Intervention: Drug: Cholecalciferol
16 Unknown  Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Procedure: Serum antibodies to infectious agents using the BioPlex 2200 and complementary EIA kits
17 Unknown  Head Circumference Growth in Children Who Develop Multiple Sclerosis Later in Life
Condition: Multiple Sclerosis
Intervention:
18 Recruiting A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device
Conditions: Multiple Sclerosis;   Relapsing-Remitting
Interventions: Other: Technical support for the RebiSmart™ device;   Other: Patient support program (MinSupport Plus)
19 Completed
Has Results
12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.
Condition: Multiple Sclerosis
Intervention: Drug: Rebif® New Formulation (RNF) using RebiSmartTM
20 Enrolling by invitation Impact of Vitamin A on Multiple Sclerosis (MS)
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Dietary Supplement: vitamin A;   Drug: Drug: placebo

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years